Background The aetiopathogenic bases of HIV-1-/highly active antiretroviral treatment
(HAART)-associated lipodystrophy (HALS) are poorly known, but this syndrome indicates …

Objective: Lipodystrophy in HIV-1–infected antiretroviral-treated patients is often associated
with opposite alterations in adipose tissue depots as follows: lipoatrophy of subcutaneous …

HIV-associated lipodystrophy or lipoatrophy, unreported before the introduction of highly
active antiretroviral therapy (HAART), was first described in 1998, and has a prevalence …

The lipodystrophy syndrome and associated metabolic alterations are the most prevalent
adverse effects in HIV-infected patients taking highly active anti-retroviral therapy (HAART) …

Objective: To determine the expressions of multiple genes in the subcutaneous adipose
tissue of HIV-positive, highly active antiretroviral therapy (HAART)-treated patients with and …

Objective: To determine liver fat content in patients with highly active antiretroviral therapy
(HAART)-associated lipodystrophy. Background: Lipodystrophy in several animal models is …

More than 15 years after the introduction of highly active antiretroviral therapy, HIV/HAART-
associated lipodystrophy syndrome still shadows the indisputable efficacy of antiretroviral …

Objective To determine whether the peripheral fat wasting (lipodystrophy), which is seen in
association with highly active antiretroviral therapy (HAART) that includes a nucleoside …

Objective To achieve a better understand of the pathophysiology of HIV-related lipoatrophy,
we compared the mRNA expression of adipocytokines in fat samples from patients and …

Objective: Antiretrovirals, especially thymidine-analogue nucleoside reverse transcriptase
inhibitors (tNRTIs), may cause the mitochondrial damage in adipose tissue that has been …